DC Vaccine in Colorectal Cancer
Pilot Study of Mature Dendritic Cell Vaccination for Resected Hypermutated Colorectal Cancer
Researchers at the University of Pennsylvania are piloting a study of a dendritic cell (DC) vaccine for colorectal cancer. DCs are rare immune cells that are unique in their ability to tell other immune cells, T-cells, to seek out tumors and attack them. The treatment will use the patient’s own DCs to multiply and prepare them to recognize their cancer in a lab before returning them to the patient via 2 IV injections. Prior to that infusion, a chemotherapy dosage will be required. Follow up continues at regular clinic visits for approximately 1 year following the final vaccine.
- Be 18 years of age and older
- Meet cancer screening requirements specific to the study
- Not be pregnant or breastfeeding
THE STUDY INVOLVES:
- Screening before the treatment
- A course of chemotherapy prior to first vaccine injection
- 2 injections of the vaccine therapy drug will be administered 8 weeks apart
- Monitoring of the patient during treatment, then follow up for 1 year.
LOCATIONS AND CONTACTS:
The study location is at the University of Pennsylvania in Philadelphia, PA. Map.
Contact: Emerging Medicine | 855.216.0098 | [email protected]
University of Pennsylvania
Or go online: